Bora Pharmaceuticals Announce on behalf of material subsidiary Bora Pharmaceutical Holdings, LLC. to acquire the product licenses and rights

1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.):Drug license

2.Date of occurrence of the event:2026/06/18

3.Date of the board of directors resolution:2026/06/18

4.Other approval date:NA

5.Amount, unit price, and total monetary amount of the transaction:
Volume and unit price: Not applicable
Total monetary amount: Less than USD 45 million

6.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed):
Trading counterparty: Aucta Pharmaceuticals, Inc.
Its relationship to the Company: non-related party

7.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer:NA

8.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction:NA

9.Matters related to the current disposal of creditors' rights (including types of collaterals of the disposed creditor's rights; if creditor's rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor's rights, currently being disposed of, over such related party):NA

10.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (those with deferral should provide a table explaining recognition):NA

11.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions:Pursuant to payment terms and conditions in the contract

12.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making unit:The reference basis for the decision of price was based on valuation reports and CPA's opinion issued by the independent appraiser, approved by the Company's board of directors for execution.

13.Net worth per share of the Company's underlying securities acquired or disposed of:NA

14.Cumulative no.of shares held (including the current transaction), their monetary amount, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment:NA

15.Current ratio of securities investment (including the current trade, as listed in article 3 of Regulations Governing the Acquisition and Disposal of Assets by Public Companies) to the total assets and equity attributable to owners of the parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present:NA

16.Broker and broker's fee:NA

17.Concrete purpose or use of the acquisition or disposal: To expand the product's economic value

18.Any dissenting opinions of directors to the present transaction:No

19.Whether the counterparty of the current transaction is a related party:No

20.Date of ratification by supervisors or approval by the Audit Committee:2026/06/18

21.Whether the CPA issued an unreasonable opinion regarding the current transaction:No

22.Name of the CPA firm: WeTec International CPAs

23.Name of the CPA: Ming-Yang Lai CPA

24.Practice certificate number of the CPA: License No. 2123

25.Whether the transaction involved in change of business model:No

26.Details on change of business model:NA

27.Details on transactions with the counterparty for the past year and the expected coming year:NA

28.Source of funds:Self owned fund

29.Date on which material information regarding the same event has been previously released:NA

30.Any other matters that need to be specified:
(1)This acquisition of the drug license and related rights is approved by the Audit Committee and the Board of Directors on June 18, 2026. The Chairman is authorized to handle all matters related to negotiation, consultation, and signing up to a maximum of US$45 million.
(2)The actual transaction amount is subject to the final signed asset (drug license) acquisition agreement.